Insulin administration using methyl and propyl paraben

A method for the treatment of diabetes which comprises administering to a nasal mucosal surface of a patient in need thereof, a composition comprising,

• (a) as an active ingredient, a medically-effective amount of insulin;
• and
• (b) as an adjuvant, an ionized or partially ionized, water soluble alkali salt of fusidic acid or a derivative thereof, said fusidic acid or derivative being present in an amount sufficient to increase the permeation of insulin through said nasal mucosal surface;
• and
• (c) as a co-adjuvant, a mixture of methylparaben and propylparaben in an amount sufficient to further increase the permeation of insulin through said nasal mucosal surface.

A method for insulin treatment of a diabetic patient in need of insulin therapy which comprises applying to the nasal mucosal surface of said diabetic, a composition comprising:

• (a) a medically-effective amount of insulin;
• and
• (b) as a nasal mucosal surface permeability enhancing adjuvant, an effective amount of sodium tauro-24,25-dihydrofusidic acid;
• and
• (c) as an increased nasal mucosal surface permeability enhancing coadjuvant, an effective amount of a mixture of methylparaben and propylparaben.

A medicinal composition for application to the nasal mucosa of a diabetic patient in need of insulin therapy, comprising:

• (a) a medically-effective amount of insulin;
• and
• (b) as an adjuvant, an ionized or partially ionized, water-soluble alkali salt of fusidic acid or a derivative thereof, in an amount sufficient to increase the permeation of insulin through said nasal mucosa;
• and
• (c) as a co-adjuvant, a mixture of methylparaben and propylparaben, in an amount sufficient to further increase the permeation of insulin through said nasal mucosa.